COMPANY PROFILE

Synthetic Design Lab

Explore full profile

Next-gen ADC platform advancing cancer therapies with a focus on human biology

San Carlos, United StatesFounded 2022Biotech & Life Sciences

Valuation $50–100M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Synthetic Design Lab

Synthetic Design Lab is at the forefront of developing next-generation Antibody-Drug Conjugates (ADCs) aimed at treating various cancer indications. The company leverages a novel SYNTHBODY therapeutic platform, emphasizing a deep understanding of human biology to create more effective therapies. By focusing on human data over animal models, Synthetic Design Lab aims to deliver on the full potential of ADCs. The company primarily serves the oncology market, targeting patients in need of advanced cancer treatments. Its business model revolves around the development and commercialization of targeted cancer therapies, potentially generating revenue through partnerships, licensing, and direct sales of its therapeutic solutions. The company was founded by Dr. Chen, a pioneer in cancer immunotherapy and protein engineering, who brings extensive experience from his tenure at Genentech and IGM Biosciences.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: San Carlos, United States
Employees: 16
Open positions: 1
Dealroom signal: 89.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Antibodies, Biotech and Pharma, Antibody-Drug Conjugate, DT and LS, science-based
Technology: Artificial Intelligence
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Apr 2025	$20M	$80M	Playground Global · Godfrey Capital	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Synthetic Design Lab website traffic

Latest recorded traffic for Synthetic Design Lab is 1.4K monthly website visits, down 60% over the last three months.

Latest monthly visits1.4K 3-month web change-60%

Monthly website visitsApr 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CBCrossBridge BioDual-payload antibody-drug conjugates to improve targeted cancer therapies and overcome tumor resistance	Houston, United States	Acquired	2	$28M	$300M
SBShizhiyuan BiotechnologyInnovative monoclonal antibody drug development and manufacturing	China	Operational
NBNeologics BioscienceClinical-stage immuno-modulating antibody therapeutics for cancer	Changzhou, China	Operational
ABAdcoris BioPharmaNext-generation antibody-drug conjugates for oncology	China	Operational
MPMinghui PharmaceuticalLate-stage biopharma developing therapeutics for cancer and immunology	Ningbo, China	Operational
MBMyt BioDiscovery of potent, selective PKMYT1 inhibitors for cyclin E-dependent cancers, enhancing ADC efficacy with oral bioavailability	London, United Kingdom	Operational
FBFirefly BioUnlocking new classes of payloads to maximize the potential of ADCs	South San Francisco, United States	Acquired
YBYouzhiyou BiopharmaceuticalA biotechnology company that develops anti-tumor bispecific antibodies	Wuhan, China	Operational